Rhabdomyosarcomas: An overview on the experimental animal models

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 7, 2012, Pages 1377-1391

  Zanola, Alessandra ^a   Rossi, Stefania ^a   Faggi, Fiorella ^a   Monti, Eugenio ^a   Fanzani, Alessandro ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Animal models; Rhabdomyosarcomas; Skeletal muscle

Indexed keywords

CARCINOGEN;

ANIMAL; DISEASE MODEL; GENE TARGETING; HUMAN; IONIZING RADIATION; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; REVIEW; RHABDOMYOSARCOMA; SKELETAL MUSCLE; SOFT TISSUE TUMOR; VIRUS INFECTION;

ANIMALS; CARCINOGENS; DISEASE MODELS, ANIMAL; GENE TARGETING; HUMANS; MESENCHYMAL STROMAL CELLS; MUSCLE, SKELETAL; RADIATION, IONIZING; RHABDOMYOSARCOMA; SOFT TISSUE NEOPLASMS; VIRUS DISEASES;

ANIMALIA;

EID: 84863102116     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01518.x     Document Type: Review

References (194)

1. Ognjanovic S, Linabery AM, Charbonneau B, et al. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer. 2009; 115: 4218-26.
2. Meyer WH, Spunt SL. Soft tissue sarcomas of childhood. Cancer Treat Rev. 2004; 30: 269-80.
3. Barr FG. The role of chimeric paired box transcription factors in the pathogenesis of pediatric rhabdomysarcoma. Cancer Res. 1999; 59: 1711s-5s.
4. Merlino G, Helman LJ. Rhabdomyosarcoma-working out the pathways. Oncogene. 1999; 18: 5340-8.
5. De Giovanni C, Landuzzi L, Nicoletti G, et al. Molecular and cellular biology of rhabdomyosarcoma. Future Oncol. 2009; 5: 1449-75.
6. Xia SJ, Pressey JG, Barr FG. Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther. 2002; 1: 97-104.
7. Tonin PN, Scrable H, Shimada H, et al. Muscle-specific gene expression in rhabdomyosarcomas and stages of human foetal skeletal muscle development. Cancer Res. 1991; 51: 5100-6.
8. Berkes CA, Tapscott SJ. MyoD and the transcriptional control of myogenesis. Semin Cell Dev Biol. 2005; 16: 585-95.
9. Bergstrom DA, Tapscott SJ. Molecular distinction between specification and differentiation in the myogenic basic helix-loop-helix transcription factor family. Mol Cell Biol. 2001; 21: 2404-12.
10. Morotti RA, Nicol KK, Parham DM, et al. An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children's Oncology Group experience. Am J Surg Pathol. 2006; 30: 962-8.
11. Charytonowicz E, Cordon-Cardo C, Matushansky I, et al. Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell? Cancer Lett. 2009; 279: 126-36.
12. Merlino G, Khanna C. Fishing for the origins of cancer. Genes Dev. 2007; 21: 1275-9.
13. Linardic CM, Downie DL, Qualman S, et al. Genetic modeling of human rhabdomyosarcoma. Cancer Res. 2005; 65: 4490-5.
14. Keller C, Capecchi MR. New genetic tactics to model alveolar rhabdomyosarcoma in the mouse. Cancer Res. 2005; 65: 7530-2.
15. Ren YX, Finckenstein FG, Abdueva DA, et al. Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res. 2008; 68: 6587-97.
16. Tsokos M, Webber BL, Parham DM, et al. Rhabdomyosarcoma. A new classification scheme related to prognosis. Arch Pathol Lab Med. 1992; 116: 847-55.
17. Sultan I, Qaddoumi I, Yaser S, et al. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2, 600 patients. J Clin Oncol. 2009; 27: 3391-7.
18. Wolden SL, Alektiar KM. Sarcomas across the age spectrum. Semin Radiat Oncol. 2010; 20: 45-51.
19. Barr FG. Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol. 1997; 19: 483-91.
20. Weber-Hall S, Anderson J, McManus A, et al. Gains, losses, and amplification of genomic material in rhabdomyosarcoma analyzed by comparative genomic hybridization. Cancer Res. 1996; 56: 3220-4.
21. Bridge JA, Liu J, Weibolt V, et al. Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization and fluorescence in situ hybridization: an intergroup rhabdomyosarcoma study. Genes Chromosomes Cancer. 2000; 27: 337-44.
22. Gordon T, McManus A, Anderson J, et al. Cytogenetic abnormalities in 42 rhabdomyosarcoma: a United Kingdom Cancer Cytogenetics Group Study. Med Pediatr Oncol. 2001; 36: 259-67.
23. Koufos A, Hansen MF, Copeland NG, et al. Loss of heterozygosity in three embryonal tumours suggests a common pathogenetic mechanism. Nature. 1985; 316: 330-4.
24. Scrable H, Cavenee W, Ghavimi F, et al. A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. Proc Natl Acad Sci USA. 1989; 86: 7480-4.
25. Scrable HJ, Witte DP, Lampkin BC, et al. Chromosomal localization of the human rhabdomyosarcoma locus by mitotic recombination mapping. Nature. 1987; 329: 645-7.
26. Loh WE, Scrable HJ, Livanos E, et al. Human chromosome 11 contains two different growth suppressor genes for embryonal rhabdomyosarcoma. Proc Natl Acad Sci USA. 1992; 89: 1755-9.
27. Anderson J, Gordon A, McManus A, et al. Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma. Neoplasia. 1999; 1: 340-8.
28. Besnard-Guérin C, Newsham I, Winqvist R, et al.A common region of loss of heterozygosity in Wilms' tumour and embryonal rhabdomyosarcoma distal to the D11S988 locus on chromosome 11p15.5. Hum Genet. 1996; 97: 163-70.
29. Davicioni E, Anderson MJ, Finckenstein FG, et al. Molecular classification of rhabdomyosarcoma-genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am J Pathol. 2009; 174: 550-64.
30. Hao Y, Crenshaw T, Moulton T, et al. Tumour-suppressor activity of H19 RNA. Nature. 1993; 365: 764-7.
31. Matsuoka S, Thompson JS, Edwards MC, et al. Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15. Proc Natl Acad Sci USA. 1996; 93: 3026-30.
32. Roeb W, Boyer A, Cavenee WK, et al.PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1. Proc Natl Acad Sci USA. 2007; 104: 18085-90.
33. Schwienbacher C, Sabbioni S, Campi M, et al. Transcriptional map of 170-kb region at chromosome 11p15.5: identification and mutational analysis of the BWR1A gene reveals the presence of mutations in tumor samples. Proc Natl Acad Sci USA. 1998; 95: 3873-8.
34. Zhan S, Shapiro DN, Helman LJ. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest. 1994; 94: 445-8.
35. Hahn H, Wojnowski L, Specht K, et al. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem. 2000; 275: 28341-4.
36. Hahn H, Wojnowski L, Zimmer AM, et al. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat Med. 1998; 4: 619-22.
37. Stratton MR, Fisher C, Gusterson BA, et al. Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res. 1989; 49: 6324-7.
38. Wilke W, Maillet M, Robinson R. H-ras-1 point mutations in soft tissue sarcomas. Mod Pathol. 1993; 6: 129-32.
39. Yoo J, Robinson RA. H-ras and K-ras mutations in soft tissue sarcoma: comparative studies of sarcomas from Korean and American patients. Cancer. 1999; 86: 58-63.
40. Galili N, Davis RJ, Fredericks WJ, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993; 5: 230-5.
41. Barr FG, Galili N, Holick J, et al. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993; 3: 113-7.
42. Davis RJ, D'Cruz CM, Lovell MA, et al. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res. 1994; 54: 2869-72.
43. Gordon AT, Brinkschmidt C, Anderson J, et al. A novel and consistent amplicon at 13q31 associated with alveolar rhabdomyosarcoma. Genes Chromosomes Cancer. 2000; 28: 220-6.
44. Berner JM, Forus A, Elkahloun A, et al. Separate amplified regions encompassing CDK4 and MDM2 in human sarcomas. Genes Chromosomes Cancer. 1996; 17: 254-9.
45. Forus A, Flørenes VA, Maelandsmo GM, et al. Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2. Cell Growth Differ. 1993; 4: 1065-70.
46. Dias P, Kumar P, Marsden HB, et al. N-myc gene is amplified in alveolar rhabdomyosarcomas (RMS) but not in embryonal RMS. Int J Cancer. 1990; 45: 593-6.
47. Driman D, Thorner PS, Greenberg ML, et al. MYCN gene amplification in rhabdomyosarcoma. Cancer. 1994; 73: 2231-7.
48. Hachitanda Y, Toyoshima S, Akazawa K, et al.N-myc gene amplification in rhabdomyosarcoma detected by fluorescence in situ hybridization: its correlation with histologic features. Mod Pathol. 1998; 11: 1222-7.
49. Iolascon A, Faienza MF, Coppola B, et al. Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma. Genes Chromosomes Cancer. 1996; 15: 217-22.
50. Graf Finckenstein F, Shahbazian V, Davicioni E, et al. PAX-FKHR function as pangenes by simultaneously inducing and inhibiting myogenesis. Oncogene. 2008; 27: 2004-14.
51. Anderson J, Ramsay A, Gould S, et al.PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma. Am J Pathol. 2001; 159: 1089-96.
52. Relaix F, Polimeni M, Rocancourt D, et al. The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo. Genes Dev. 2003; 17: 2950-65.
53. Goldstein M, Meller I, Issakov J, et al. Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors. Neoplasia. 2006; 8: 332-43.
54. Gordon A, McManus A, Anderson J, et al. Chromosomal imbalances in pleomorphic rhabdomyosarcomas and identification of the alveolar rhabdomyosarcoma-associated PAX3-FOXO1A fusion gene in one case. Cancer Genet Cytogenet. 2003; 140: 73-7.
55. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990; 250: 1233-8.
56. Felix CA, Kappel CC, Mitsudomi T, et al. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res. 1992; 52: 2243-7.
57. Diller L, Sexsmith E, Gottlieb A, et al. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest. 1995; 95: 1606-11.
58. Taylor AC, Shu L, Danks MK, et al. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol. 2000; 35: 96-103.
59. Lindor NM, McMaster ML, Lindor CJ, et al. Concise handbook of familial cancer susceptibility syndromes - second edition. J Natl Cancer Inst Monogr. 2008; 38: 1-93.
60. Keleti J, Quezado MM, Abaza MM, et al. The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Am J Pathol. 1996; 149: 143-51.
61. Cam H, Griesmann H, Beitzinger M, et al. p53 family members in myogenic differentiation and rhabdomyosarcoma development. Cancer Cell. 2006; 10: 281-93.
62. Kohashi K, Oda Y, Yamamoto H, et al. Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype. J Cancer Res Clin Oncol. 2008; 134: 1097-103.
63. Taulli R, Scuoppo C, Bersani F, et al. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res. 2006; 66: 4742-9.
64. Takayama H, LaRochelle WJ, Sharp R, et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA. 1997; 94: 701-6.
65. Ferracini R, Olivero M, Di Renzo MF, et al. Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene. 1996; 12: 1697-705.
66. Ginsberg JP, Davis RJ, Bennicelli JL, et al. Up-regulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcoma. Cancer Res. 1998; 58: 3542-6.
67. Rees H, Williamson D, Papanastasiou A, et al. The MET receptor tyrosine kinase contributes to invasive tumour growth in rhabdomyosarcomas. Growth Factors. 2006; 24: 197-208.
68. Sharp R, Recio JA, Jhappan C, et al. Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med. 2002; 8: 1276-80.
69. Kim SY, Toretsky JA, Scher D, et al. The role of IGF-1R in pediatric malignancies. Oncologist 2009; 14: 83-91.
70. Ayalon D, Glaser T, Werner H. Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm IGF Res. 2001; 11: 289-97.
71. Blandford MC, Barr FG, Lynch JC, et al. Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2006; 46: 329-38.
72. Khan J, Bittner ML, Saal LH, et al. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc Natl Acad Sci USA. 1999; 96: 13264-9.
73. Astolfi A, De Giovanni C, Landuzzi L, et al. Identification of new genes related to the myogenic differentiation arrest of human rhabdomyosarcoma cells. Gene. 2001; 274: 139-49.
74. Ganti R, Skapek SX, Zhang J, et al. Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. Mod Pathol. 2006; 19: 1213-20.
75. Taniguchi E, Nishijo K, McCleish AT, et al. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene. 2008; 27: 6550-60.
76. Onisto M, Slongo ML, Gregnanin L, et al. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines. Int J Oncol. 2005; 27: 791-8.
77. Gee MF, Tsuchida R, Eichler-Jonsson C, et al. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid. Oncogene. 2005; 24: 8025-37.
78. Wang W, Slevin M, Kumar S, et al. The cooperative transforming effects of PAX3-FKHR and IGF-II on mouse myoblasts. Int J Oncol. 2005; 27: 1087-96.
79. Taylor JG, Cheuk AT, Tsang PS, et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest. 2009; 119: 3395-407.
80. Williamson D, Selfe J, Gordon T, et al. Role for amplification and expression of glypican-5 in rhabdomyosarcoma. Cancer Res. 2007; 67: 57-65.
81. Astolfi A, Nanni P, Landuzzi L, et al. An anti-apoptotic role for NGF receptors in human rhabdomyosarcoma. Eur J Cancer. 2001; 37: 1719-25.
82. Bouché M, Canipari R, Melchionna R, et al. TGF-beta autocrine loop regulates cell growth and myogenic differentiation in human rhabdomyosarcoma cells. FASEB J. 2000; 14: 1147-58.
83. Ricaud S, Vernus B, Duclos M, et al. Inhibition of autocrine secretion of myostatin enhances terminal differentiation in human rhabdomyosarcoma cells. Oncogene. 2003; 22: 8221-32.
84. Langley B, Thomas M, McFarlane C, et al. Myostatin inhibits rhabdomyosarcoma cell proliferation through an Rb-independent pathway. Oncogene. 2004; 23: 524-34.
85. Rossi S, Stoppani E, Puri PL, et al. Differentiation of human rhabdomyosarcoma RD cells is regulated by reciprocal, functional interactions between myostatin, p38 and extracellular regulated kinase signalling pathways. Eur J Cancer. 2011; 47: 1095-105.
86. Tomescu O, Xia SJ, Strezlecki D, et al. Inducible short-term and stable long-term cell culture systems reveal that the PAX3-FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expression. Lab Invest. 2004; 84: 1060-70.
87. Ebauer M, Wachtel M, Niggli FK, et al. Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR. Oncogene. 2007; 26: 7267-81.
88. Riuzzi F, Sorci G, Donato R. RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth. Am J Pathol. 2007; 171: 947-61.
89. Davicioni E, Finckenstein FG, Shahbazian V, et al. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res. 2006; 66: 6936-46.
90. Puri PL, Wu Z, Zhang P, et al. Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells. Genes Dev. 2000; 14: 574-84.
91. Tapscott SJ, Thayer MJ, Weintraub H. Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science. 1993; 259: 1450-3.
92. Yang Z, MacQuarrie KL, Analau E, et al. MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested myoblast phase to a differentiated state. Genes Dev. 2009; 23: 694-707.
93. Cen L, Hsieh FC, Lin HJ, et al. PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound. Br J Cancer. 2007; 97: 785-91.
94. Marampon F, Ciccarelli C, Zani BM. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors. Mol Cancer. 2006; 5: 31.
95. Hoovers JM, Kalikin LM, Johnson LA, et al. Multiple genetic loci within 11p15 defined by Beckwith-Wiedemann syndrome rearrangement breakpoints and subchromosomal transferable fragments. Proc Natl Acad Sci USA. 1995; 92: 12456-60.
96. Ferrari A, Bisogno G, Macaluso A, et al. Soft-tissue sarcomas in children and adolescents with neurofibromatosis type 1. Cancer. 2007; 109: 1406-12.
97. Aoki Y, Niihori T, Kawame H, et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet. 2005; 37: 1038-40.
98. Gorlin RJ. Nevoid basal cell carcinoma (Gorlin) syndrome. Genet Med. 2004; 6: 530-9.
99. Kleinerman RA, Tucker MA, Abramson DH, et al. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst. 2007; 99: 24-31.
100. Hanks S, Coleman K, Summersgill B, et al. Comparative genomic hybridization and BUB1B mutation analyses in childhood cancers associated with mosaic variegated aneuploidy syndrome. Cancer Lett. 2006; 239: 234-8.
101. Kratz CP, Holter S, Etzler J, et al. Rhabdomyosarcoma in patients with constitutional mismatch-repair-deficiency syndrome. J Med Genet. 2009; 46: 418-20.
102. Miller RW, Rubinstein JH. Tumors in Rubinstein-Taybi syndrome. Am J Med Genet. 1995; 56: 112-5.
103. Gilman JP, Herchen H. The effect of physical form of implant on nickel sulphide tumourigenesis in the rat. Acta Unio Int Contra Cancrum. 1963; 19: 615-9.
104. Gilman JP. Metal carcinogenesis. II. A study on the carcinogenic activity of cobalt, copper, iron, and nickel compounds. Cancer Res. 1962; 22: 158-62.
105. Maenza RM, Pradhan AM, Sunderman FW. Rapid induction of sarcomas in rats by combination of nickel sulfide and 3, 4-benzpyrene. Cancer Res. 1971; 31: 2067-71.
106. Damjanov I, Sunderman FW, Mitchell JM, et al. Induction of testicular sarcomas in Fischer rats by intratesticular injection of nickel subsulfide. Cancer Res. 1978; 38: 268-76.
107. Hildebrand HF, Biserte G. Cylindrical laminated bodies in nickel-subsulphide-induced rhabdomyosarcoma in rabbits. Eur J Cell Biol. 1979; 19: 276-80.
108. Nanni P, Azzarello G, Tessarollo L, et al. In vitro differentiation of rhabdomyosarcomas induced by nickel or by Moloney murine sarcoma virus. Br J Cancer. 1991; 63: 736-42.
109. Edgar JA, Colegate SM, Boppré M, et al. Pyrrolizidine alkaloids in food: a spectrum of potential health consequences. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2011; 28: 308-24.
110. Fu PP, Xia Q, Lin G, et al. Pyrrolizidine alkaloids-genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab Rev. 2004; 36: 1-55.
111. Allen JR, Hsu IC, Carstens LA. Dehydroretronecine-induced rhabdomyosarcomas in rats. Cancer Res. 1975; 35: 997-1002.
112. Toth B, Patil K, Erickson J, et al. Carcinogenesis by benzenediazonium sulfate in mice. In Vivo. 1998; 12: 379-82.
113. Toth B, Patil K, Taylor J, et al. Cancer induction in mice by 4-hydroxybenzenediazonium sulfate of the Agaricus xanthodermus mushroom. In Vivo. 1989; 3: 301-5.
114. Toth B, Taylor J, Mattson B, et al. Tumor induction by 4-(methyl)benzenediazonium sulfate in mice. In Vivo. 1989; 3: 17-21.
115. Bouvier G, Poirier S, Shao YM, et al. Epstein-Barr virus activators, mutagens and volatile nitrosamines in preserved food samples from high-risk areas for nasopharyngeal carcinoma. IARC Sci Publ. 1991; 105: 204-9.
116. Bunton TE, Wolfe MJ. N-methyl-N'-nitro-N-nitrosoguanidine-induced neoplasms in medaka (Oryzias latipes). Toxicol Pathol. 1996; 24: 323-30.
117. Spitsbergen JM, Tsai HW, Reddy A, et al. Neoplasia in zebrafish (Danio rerio) treated with N-methyl-N'-nitro-N-nitrosoguanidine by three exposure routes at different developmental stages. Toxicol Pathol. 2000; 28: 716-25.
118. Lijinsky W, Saavedra JE, Reuber MD. Organ-specific carcinogenesis in rats by methyl- and ethylazoxyalkanes. Cancer Res. 1985; 45: 76-9.
119. Sohn OS, Fiala ES, Requeijo SP, et al. Differential effects of CYP2E1 status on the metabolic activation of the colon carcinogens azoxymethane and methylazoxymethanol. Cancer Res. 2001; 61: 8435-40.
120. Chen J, Huang XF. The signal pathways in azoxymethane-induced colon cancer and preventive implications. Cancer Biol Ther. 2009; 8: 1313-7.
121. Cattabeni F, Di Luca M. Developmental models of brain dysfunctions induced by targeted cellular ablations with methylazoxymethanol. Physiol Rev. 1997; 77: 199-215.
122. Hawkins W, Fournie J, Overstreet R, et al. Rhabdomyosarcoma in the Japanese medaka, oryzias-latipes (temminck and schlegel) and guppy, poecilia-reticulata peters. J Fish Dis. 1988; 11: 259-66.
123. Warshawsky D. Polycyclic aromatic hydrocarbons in carcinogenesis. Environ Health Perspect. 1999; 107: 317-9.
124. Spitsbergen JM, Tsai HW, Reddy A, et al. Neoplasia in zebrafish (Danio rerio) treated with 7, 12-dimethylbenz[a]anthracene by two exposure routes at different developmental stages. Toxicol Pathol. 2000; 28: 705-15.
125. Taguchi S, Kuriwaki K, Souda M, et al. Induction of sarcomas by a single subcutaneous injection of 7, 12-dimethylbenz[a]anthracene into neonatal male Sprague-Dawley rats: histopathological and immunohistochemical analyses. Toxicol Pathol. 2006; 34: 336-47.
126. Westwood FR, Longstaff E, Butler WH. Cellular progression of neoplasia in the subcutis of mice after implantation of 3, 4-benzpyrene. Br J Cancer. 1979; 39: 761-72.
127. Shimizu Y, Nakatsuru Y, Ichinose M, et al. Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc Natl Acad Sci USA. 2000; 97: 779-82.
128. Kalinich JF, Emond CA, Dalton TK, et al. Embedded weapons-grade tungsten alloy shrapnel rapidly induces metastatic high-grade rhabdomyosarcomas in F344 rats. Environ Health Perspect. 2005; 113: 729-34.
129. Gupta A, Andrews KL, McDaniel KM, et al. Experimental induction of rhabdomyosarcoma in mice with fractionated doses of beta-irradiation. J Cancer Res Clin Oncol. 1999; 125: 257-67.
130. Perk K, Shachat DA, Moloney JB. Pathogenesis of a rhabdomyosarcoma (undifferentiated type) in rats induced by a murine sarcoma virus (Moloney). Cancer Res. 1968; 28: 1197-206.
131. Teitz T, Chang JC, Kitamura M, et al. Rhabdomyosarcoma arising in transgenic mice harboring the beta-globin locus control region fused with simian virus 40 large T antigen gene. Proc Natl Acad Sci USA. 1993; 90: 2910-4.
132. Köbbert C, Möllmann C, Schäfers M, et al. Transgenic model of cardiac rhabdomyosarcoma formation. J Thorac Cardiovasc Surg. 2008; 136: 1178-86.
133. Malkin D, Chilton-MacNeill S, Meister LA, et al. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome. Oncogene. 2001; 20: 4441-9.
134. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009; 9: 749-58.
135. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992; 356: 215-21.
136. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994; 4: 1-7.
137. Harvey M, McArthur MJ, Montgomery CA, et al. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet. 1993; 5: 225-9.
138. Harvey M, McArthur MJ, Montgomery CA, et al. Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J. 1993; 7: 938-43.
139. Fleischmann A, Jochum W, Eferl R, et al. Rhabdomyosarcoma development in mice lacking Trp53 and Fos: tumor suppression by the Fos protooncogene. Cancer Cell. 2003; 4: 477-82.
140. Jochum W, Passegué E, Wagner EF. AP-1 in mouse development and tumorigenesis. Oncogene. 2001; 20: 2401-12.
141. Ricci C, Landuzzi L, Rossi I, et al. Expression of HER/erbB family of receptor tyrosine kinases and induction of differentiation by glial growth factor 2 in human rhabdomyosarcoma cells. Int J Cancer. 2000; 87: 29-36.
142. Andrechek ER, Hardy WR, Girgis-Gabardo AA, et al. ErbB2 is required for muscle spindle and myoblast cell survival. Mol Cell Biol. 2002; 22: 4714-22.
143. Nanni P, Nicoletti G, De Giovanni C, et al. Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. Cancer Res. 2003; 63: 2728-32.
144. Tsumura H, Yoshida T, Saito H, et al. Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice. Oncogene. 2006; 25: 7673-9.
145. Doyle B, Morton JP, Delaney DW, et al. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma. J Pathol. 2010; 222: 129-37.
146. Post SM, Lozano G. You can win by losing: p53 mutations in rhabdomyosarcomas. J Pathol. 2010; 222: 124-8.
147. Anderson MJ, Shelton GD, Cavenee WK, et al. Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3. Proc Natl Acad Sci USA. 2001; 98: 1589-94.
148. Finckenstein FG, Davicioni E, Osborn KG, et al. Transgenic mice expressing PAX3-FKHR have multiple defects in muscle development, including ectopic skeletal myogenesis in the developing neural tube. Transgenic Res. 2006; 15: 595-614.
149. Keller C, Arenkiel BR, Coffin CM, et al. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev. 2004; 18: 2614-26.
150. Chin L, Pomerantz J, DePinho RA. The INK4a/ARF tumor suppressor: one gene-two products-two pathways. Trends Biochem Sci. 1998; 23: 291-6.
151. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol. 2001; 2: 731-7.
152. Chardin P, Yeramian P, Madaule P, et al.N-ras gene activation in the RD human rhabdomyosarcoma cell line. Int J Cancer. 1985; 35: 647-52.
153. Bos JL, Verlaan-de Vries M, Jansen AM, et al. Three different mutations in codon 61 of the human N-ras gene detected by synthetic oligonucleotide hybridization. Nucleic Acids Res. 1984; 12: 9155-63.
154. Martinelli S, McDowell HP, Vigne SD, et al. RAS signaling dysregulation in human embryonal Rhabdomyosarcoma. Genes Chromosomes Cancer. 2009; 48: 975-82.
155. Chen Y, Takita J, Hiwatari M, et al. Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies. Genes Chromosomes Cancer. 2006; 45: 583-91.
156. Kratz CP, Rapisuwon S, Reed H, et al. Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am J Med Genet C Semin Med Genet. 2011; 157: 83-9.
157. Kratz CP, Steinemann D, Niemeyer CM, et al. Uniparental disomy at chromosome 11p15.5 followed by HRAS mutations in embryonal rhabdomyosarcoma: lessons from Costello syndrome. Hum Mol Genet. 2007; 16: 374-9.
158. Langenau DM, Keefe MD, Storer NY, et al. Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev. 2007; 21: 1382-95.
159. Jeffers M, Rong S, Woude GF. Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J Mol Med (Berl). 1996; 74: 505-13.
160. Matsumoto K, Nakamura T. Emerging multipotent aspects of hepatocyte growth factor. J Biochem. 1996; 119: 591-600.
161. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer. 2002; 2: 289-300.
162. Danilkovitch-Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest. 2002; 109: 863-7.
163. Sakata H, Takayama H, Sharp R, et al. Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers. Cell Growth Differ. 1996; 7: 1513-23.
164. Otsuka T, Takayama H, Sharp R, et al. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res. 1998; 58: 5157-67.
165. Serrano M, Lee H, Chin L, et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 1996; 85: 27-37.
166. Zacksenhaus E, Jiang Z, Chung D, et al. pRb controls proliferation, differentiation, and death of skeletal muscle cells and other lineages during embryogenesis. Genes Dev. 1996; 10: 3051-64.
167. Pomerantz J, Schreiber-Agus N, Liégeois NJ, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 1998; 92: 713-23.
168. Epstein JA, Shapiro DN, Cheng J, et al. Pax3 modulates expression of the c-Met receptor during limb muscle development. Proc Natl Acad Sci USA. 1996; 93: 4213-8.
169. Tatsumi R, Anderson JE, Nevoret CJ, et al. HGF/SF is present in normal adult skeletal muscle and is capable of activating satellite cells. Dev Biol. 1998; 194: 114-28.
170. Lum L, Beachy PA. The Hedgehog response network: sensors, switches, and routers. Science. 2004; 304: 1755-9.
171. Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 2001; 15: 3059-87.
172. Pazzaglia S. Ptc1 heterozygous knockout mice as a model of multi-organ tumorigenesis. Cancer Lett. 2006; 234: 124-34.
173. Kappler R, Bauer R, Calzada-Wack J, et al. Profiling the molecular difference between patched- and p53-dependent rhabdomyosarcoma. Oncogene. 2004; 23: 8785-95.
174. Zibat A, Uhmann A, Nitzki F, et al. Time-point and dosage of gene inactivation determine the tumor spectrum in conditional Ptch knockouts. Carcinogenesis. 2009; 30: 918-26.
175. Rubin BP, Nishijo K, Chen HI, et al. Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell. 2011; 19: 177-91.
176. Lee Y, Kawagoe R, Sasai K, et al. Loss of suppressor-of-fused function promotes tumorigenesis. Oncogene. 2007; 26: 6442-7.
177. Svärd J, Heby-Henricson K, Henricson KH, et al. Genetic elimination of Suppressor of fused reveals an essential repressor function in the mammalian Hedgehog signaling pathway. Dev Cell. 2006; 10: 187-97.
178. Taylor MD, Liu L, Raffel C, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet. 2002; 31: 306-10.
179. Partridge T. Animal models of muscular dystrophy-what can they teach us? Neuropathol Appl Neurobiol. 1991; 17: 353-63.
180. Bulfield G, Siller WG, Wight PA, et al. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA. 1984; 81: 1189-92.
181. Sicinski P, Geng Y, Ryder-Cook AS, et al. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science. 1989; 244: 1578-80.
182. Hoffman EP, Morgan JE, Watkins SC, et al. Somatic reversion/suppression of the mouse mdx phenotype in vivo. J Neurol Sci. 1990; 99: 9-25.
183. Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987; 51: 919-28.
184. Ervasti JM, Campbell KP. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J Cell Biol. 1993; 122: 809-23.
185. Chamberlain JS, Metzger J, Reyes M, et al. Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J. 2007; 21: 2195-204.
186. Fernandez K, Serinagaoglu Y, Hammond S, et al. Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts. Am J Pathol. 2010; 176: 416-34.
187. Allamand V, Campbell KP. Animal models for muscular dystrophy: valuable tools for the development of therapies. Hum Mol Genet. 2000; 9: 2459-67.
188. Duclos F, Straub V, Moore SA, et al. Progressive muscular dystrophy in alpha-sarcoglycan-deficient mice. J Cell Biol. 1998; 142: 1461-71.
189. Weller B, Karpati G, Carpenter S. Dystrophin-deficient mdx muscle fibers are preferentially vulnerable to necrosis induced by experimental lengthening contractions. J Neurol Sci. 1990; 100: 9-13.
190. Petrof BJ, Shrager JB, Stedman HH, et al. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA. 1993; 90: 3710-4.
191. Camboni M, Hammond S, Martin LT, et al. Induction of a regenerative microenvironment in skeletal muscle is sufficient to induce embryonal rhabdomyosarcoma in p53-deficient mice. J Pathol. 2011; 226: 40-9.
192. Sher RB, Cox GA, Mills KD, et al. Rhabdomyosarcomas in aging a/j mice. PLoS ONE. 2011; 6: e23498.
193. Ho M, Post CM, Donahue LR, et al. Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. Hum Mol Genet. 2004; 13: 1999-2010.
194. Bittner RE, Anderson LV, Burkhardt E, et al. Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B. Nat Genet. 1999; 23: 141-2.